Belzutifan is a novel HIF-2α inhibitor that has been approved for use in CNS hemangioblastomas, clear cell renal carcinoma and pancreatic neuroendocrine tumors. This evidence concerns the gene EPAS1 and pancreatic neuroendocrine tumor.